The authors of One more paper documented the administration of HBOT as adjuvant therapy for acute macular neuroretinopathy in systemic lupus erythematosus in conjunction with immunosuppression in two patients [eleven].Even though CRAO is the only vascular condition on the retina the place HBOT is recommended through the UHMS, there are various clai